SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Catalent, Inc. and Viking Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.

Catalent, Inc.: A Steady Climb

Since 2014, Catalent has seen a consistent rise in SG&A expenses, peaking at approximately $935 million in 2024. This represents a nearly 180% increase from 2014, reflecting the company's expansion and investment in operational capabilities.

Viking Therapeutics, Inc.: A Different Path

Viking Therapeutics, on the other hand, started with modest SG&A expenses, around $1.2 million in 2014. By 2023, these expenses surged to $37 million, marking a staggering 2,900% increase. This dramatic rise underscores Viking's aggressive growth strategy.

The data highlights the distinct financial strategies of these two companies, offering valuable insights for investors and industry analysts.